Publications

A phase 1 study of the IAP inhibitor xevinapant (Debio 1143) to evaluate food effect and drug-drug interactions with a…

A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid…

DEBIO 1143, an IAP inhibitor, reverses ovarian cancer cells carboplatin resistance and triggers apoptotic or necroptotic cell death

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in…

SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer

The inhibitor of apoptosis protein (IAP) antagonist Debio 1143 enhances the immune response to anti-PD1/L1 inhibitors in vitro and in…

Chemosensitization to Carboplatin and Paclitaxel by IAP Inhibitor Debio 1143 in Ovarian Cancer Cell Lines: Signature Identification for Potential Patient…

Paclitaxel-Carboplatin With The Oral Iap Inhibitor Debio1143 In A Subset Of Patients With Recurrent Epithelial Ovarian Cancer (EOC): Phase I

Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients